

02-07-00

A

PATENT

ATTORNEY DOCKET NO. ROBU.003.01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Jens-Ulrich Buelow

) Examiner: Not Yet Assigned

Serial No.: Not Yet Assigned

) Art Unit: Not Yet Assigned

Filed: February 4, 2000

) UTILITY PATENT APPLICATION

For: Human Polyclonal Antibodies From
Genetically Engineered Animals

) TRANSMITTAL

BOX PATENT APPLICATION

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

This is a request for filing a patent application under 37 C.F.R. § 1.53(b) in the name
of inventor: **JENS-ULRICH BUELOW**.

For: Human Polyclonal Antibodies From Genetically Engineered Animals

This application is a [] Continuation [] Divisional [X] Continuation-in-part of
prior U.S. provisional application serial no. 60/118,810, filed February 5, 1999, U.S.
provisional application serial no. 60/131,398, filed April 28, 1999, and U.S. provisional
application serial no. 60/134,674, filed May 18, 1999, from which priority under 35 U.S.C.
§ 120 is claimed.

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No.: EL398977621US

Date of Deposit: 2/4/00

I hereby certify under 37 C.F.R. 1.10 that this correspondence is
being deposited with the United States Postal Service as "Express
Mail Post Office to Addressee" with sufficient postage on the date
indicated above and is addressed to the Commissioner of Patents
and Trademarks, Washington, D.C., 20231.

(Signature)

JACOB ZWELG

(Printed Name)

02/04/00
JC759 U.S. PTO

JC678 U.S. PTO
09/498537
02/04/00

09498537 020400

Application Elements:

20 Pages of Specification, Claims and Abstract

☒ Declaration

☒ Unexecuted Combined Inventor Declaration and Power of Attorney

☐ Copy from prior application (37 CFR 1.63(d) for a continuation or divisional).

The entire disclosure of the prior application from which a copy of the declaration is herein supplied is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

☐ Deletion of inventors Signed statement attached deleting inventor(s) named in the prior application, *see* CFR 1.63(d)(2) and 1.33(b).

Accompanying Application Parts:

☐ Assignment and Assignment Recordation Cover Sheet (recording fee of \$40.00 enclosed)

☐ Power of Attorney

☐ 37 CFR 3.73(b) Statement by Assignee

☐ Information Disclosure Statement with Form 1449

☐ Copies of IDS Citations

☐ Preliminary Amendment

☒ Return Receipt Postcard

☒ Small Entity Statement(s) ☒ Statement filed in prior application. Status still proper and desired.

☐ Other:

☐ A sequence listing.

☐ paper copy.

☐ computer readable copy.

☐ Statement in Compliance with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence.

Claim For Foreign Priority

☐ Priority of _____ Application No. _____ filed on _____ is claimed under 35 U.S.C. § 119

☐ The certified copy has been filed in prior application U.S. Application No. _____

☐ the certified copy will follow.

Extension of Time for Prior Pending Application

☐ A Petition for Extension of Time is being concurrently filed in the prior pending application. A copy of the Petition for Extension of Time is attached.

Amendments

- ☐ Amend the specification by inserting before the first line the sentence: "This is a
☐ Continuation ☐ Continuation-in-part ☐ Divisional application of copending
prior
☐ Application No. _____ filed on _____.
☐ International Application _____ filed on _____, which
designated the United States, disclosure of which is incorporated herein by reference."
☐ Cancel in this application original claims _____ of the prior application before
calculating the filing fee

Fee Calculation (37 CFR § 1.16):

	(Col. 1)	(Col. 2)	<u>SMALL ENTITY</u>		<u>OTHER THAN A SMALL ENTITY</u>	
<u>FOR:</u>	<u>NO. FILED</u>	<u>NO. EXTRA</u>	<u>RATE</u>	<u>FEE</u>	<u>RATE</u>	<u>FEE</u>
Basic Fee			\$380	\$380	\$760	\$
Total Claims	32	12	\$ 9	\$108	\$ 18	\$
Indep Claims	5	2	\$ 39	\$78	\$ 39	\$
<input type="checkbox"/> Multiple Dependent Claims			\$130	\$0	\$260	\$
Total Filing Fee:				\$566		

TOTAL FEES: \$566.00

- ☒ A check including the amount of the above-indicated TOTAL FEES is attached.
☐ Please charge Deposit Account No.18-0020 in the amount of \$ _____.
☐ No fee is required.
☒ Conditional Petition for Extension of Time: An extension of time is requested in the
present and/or the above-referenced parent application to provide for timely filing if an
extension of time is still required after all papers filed with this transmittal have been
considered.

- [X] The Commissioner is hereby authorized to charge any underpayment of the following fees associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 18-0020.
- [X] Any filing fees under 37 CFR 1.16 including fees for the presentation of extra claims.
- [X] Any parent application processing fees under 37 CFR 1.17.
- [X] A **duplicate** copy of this sheet is attached for accounting purposes.

Respectfully submitted,

Dated: February 4, 2000

By: Barbara Rae-Venter
Barbara Rae-Venter, Ph.D.
Reg. No. 32,750

Rae-Venter Law Group, P.C.
P.O. Box 60039
Palo Alto, California 94306
Telephone: (650) 328-4400
Facsimile: (650) 328-4477

BRV/jsz
Enclosures

APPLICATION
FOR
UNITED STATES LETTERS PATENT

**TITLE: HUMAN POLYCLONAL ANTIBODIES FROM
GENETICALLY ENGINEERED ANIMALS**

INVENTOR: JENS-ULRICH BUELOW

Certificate of Express Mailing

Express Mail Label Number: EL39897762US

Date of Deposit 2/4/00

I hereby certify Under 37 C F R. 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above, and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Jacob Zweig
(Signature)

Jacob Zweig
(Printed Name)

**HUMAN POLYCLONAL ANTIBODIES FROM GENETICALLY
ENGINEERED ANIMALS**

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. provisional application serial no. 60/118,810, filed February 5, 1999, U.S. provisional application serial no. 60/131,398, filed April 28, 1999, and U.S. provisional application serial no. 60/134,674, filed May 18, 1999, which disclosures are incorporated herein by reference.

INTRODUCTION

Field of the Invention

The field of this invention is substantially human polyclonal antisera for prophylactic and therapeutic treatment of humans.

Background

The therapy of infectious diseases caused by bacteria, fungi, virus and parasites is largely based on chemotherapy. However, the emergence of drug-resistant organisms requires the continuous development of new antibiotics. At the same time the control of infections is threatened by the emergence of new pathogens. The increasing number of immunocompromised individuals due to malnutrition, AIDS, medical therapies of cancer, autoimmune diseases and organ transplantation decreases the efficacy of antibiotic therapy and increases the difficulty of controlling infections.

Therapies of patients with malignancies and cancer are also based on chemotherapy. However, many of these therapies are ineffective and the mortality of diseased patients is high. Advances in monoclonal antibody technology have provided little improvement because of the immunogenicity of the monoclonal antibodies and their lack of potency. Anti-

idiotypic antibody responses in patients undergoing monoclonal antibody therapy can render the antibody therapy ineffective.

Therapy of steroid resistant rejection of transplanted organs requires the uses of biological reagents (monoclonal or polyclonal antibody preparations) that reverse the ongoing alloimmune response in the transplant recipient. However, immunogenicity of antibody preparations may render such therapy ineffective and prevent rejection reversal. As a consequence, a transplanted organ may be rejected. Similarly, antibody therapies of autoimmune disease patients are of limited success due to the immunogenicity of antibody preparations. While humanization of antibodies decreases immunogenicity, the effectiveness of such antibodies is limited by anti-idiotypic antibody responses and the lack of potency of monoclonal antibodies. Non-immunogenic, potent reagents for the modulation of immune responses have to be developed.

Polyclonal antibody therapy for the treatment of infectious diseases was introduced at the end of the last century. By the 1930s, serum therapy was used for treatment of bacterial and viral infections including pneumonia, meningitis, scarlet fever, whooping cough, anthrax, botulism, gangrene, tetanus, brucellosis, dysentery, tularemia, diphtheria, measles, poliomyelitis mumps and chickenpox. However, the systemic administration of animal sera caused fevers, chills, and allergic reactions. Serum sickness occurred in 10-50% of treated individuals.

The potential of using antibodies in the treatment of a variety of indications is very high. The ability to specifically bind to a target entity provides diverse opportunities to sequester and destroy the entity. However, as demonstrated above, there have been many impediments to the use of heterologous and humanized antibodies. The limitations of monoclonal antibodies adds the additional impediment of reduced affinity. Thus, there is a pressing need to find alternative modalities which provide protection against infectious disease and malignancies or the immunomodulation of transplant recipients and autoimmune disease patients.

Relevant Literature

Antibody-based therapies in infectious diseases were recently reviewed by A. Casadevall and M. D. Scharff, *Clinical Infectious Diseases* 1995; 150-161.

The use of antibodies for the treatment of cancer and malignancies was recently reviewed by C. Botti, A. Marinetti, S. Nerini-Molteni, and L Ferrari, *Int J Biol Markers* 1997; 12(4):141-147; D.R. Anderson, A. Grillo-Lopez, C. Varns, and K.S. Chambers, *Biochem Soc Trans* 1997; 25(2):705-708; C. Renner, L. Trumper, and M. Pfreundschuh, *Leukemia* 1997; 11 Suppl 2:S55-59; B. Bodey, S.E. Siegel, and H.E. Kaiser, *Anticancer Res* 1996; 16(2):661-674.

The use of polyclonal antibody preparations for the treatment of transplant rejection was recently reviewed by N. Bonnefoy-Berard and J.P. Revillard, *J Heart Lung Transplant* 1996; 15(5):435-442; C. Colby, C.A. Stoukides, and T.R. Spitzer, *Ann Pharmacother* 1996; 30(10):1164-1174; M.J. Dugan, T.E. DeFor, M. Steinbuch, and A.H. Filipovich, *Ann Hematol* 1997; 75(1-2):41-46.

The use of polyclonal antibody therapies for autoimmune diseases has been described by W. Cendrowski, *Boll Ist Sieroter Milan* 1997; 58(4):339-343; L.K. Kastrukoff, D.R. McLean, and T.A. McPherson, *Can J Neurol Sci* 1978; 5(2):175-178; J.E. Walker, M.M. Hoehn, and N. Kashiwagi, *J Neurol Sci* 1976; 29(2-4):303-309.

The depletion of fat cells using antibody preparations has been described by L. De Clercq, J. Mourot, C. Genart, V. Davidts, and C. Boone, *J Anim Sci* 1997; 75(7):1791-1797; J.T. Wright and G.J. Hausman, *Obes Res* 1995; 3(3):265-272.

The cloning of animals from cells has been described by T. Wakayama, A.C.F. Perry, M. Zuccotti, K.R. Johnson and R. Yanagachi, *Nature* 1998; 394:369-374; J.B. Cibelli, S.L. Stice, P.J. Golueke, J.J. Kane, J. Jerry, C. Blackwell, A. Ponce de Leon, and J.M. Robl, *Science* 1998; 280:1256-1258; J.B. Cibelli, S. L. Stice, P. J. Golueke, J.K. Kane, J. Jerry, C. Blackwell, F. Abel de Leon, and J. Robl, *Nature Biotechnology* 1998; 16:642-646; A. E.

Schnieke, A.J. Kind, W.A. Ritchie, K. Mycock, A.R. Scott, M. Ritchie, I. Wilmut, A. Colman A, and K.H. Campbell, Science 1997; 278(5346):2130-2133; K.H. Campbell, J. McWhir, W.A. Ritchie, and I. Wilmut, Nature 1996; 380(6569):64-66.

Production of antibodies from transgenic animals is described in U.S. Patent nos. 5,814,318; 5,545,807; and 5,570,429. Homologous recombination for chimeric mammalian hosts is exemplified in U.S. Patent no. 5,416,260. A method for introducing DNA into an embryo is described in U.S. Patent no. 5,567,607. Maintenance and expansion of embryonic stem cells is described in U.S. Patent no. 5,453,357.

SUMMARY OF THE INVENTION

Methods are provided for the production of substantially human polyclonal antisera to a specific antigen, where a transgenic domestic animal comprising genetically altered light and heavy chain immunoglobulin loci and at least a portion of human light and heavy chain immunoglobulin loci are provided. The method employs stepwise modification of a domestic animal in which the antibody repertoire is diversified predominantly by gene conversion (e.g rabbits, sheep, pigs, cows). The method involves replacement by homologous recombination of endogenous elements of the immunoglobulin loci with the corresponding human counterparts, in particular, replacement of one or several exons encoding constant regions of heavy and light chain and one or several variable region elements including the one proximal to the D region locus. In animals, where antibody diversity is generated predominantly by gene conversion, replacement of the V region most proximal to the D region with a human V region element results in expression of the human V element in the majority of immunoglobulins. This genetic engineering is followed by breeding hosts of the same species and selecting for a host which is capable of responding to immunization with production of substantially human antisera with host glycosylation, the immunoglobulin having at least a functional portion of the human heavy chain. Animals expressing the substantially human protein sequence immunoglobulins are used for the generation of polyclonal antibody preparations by immunization with immunogens of interest, particularly, immunogens which initiate antibody production which has therapeutic activity. After purification of the antisera, such antisera may be used, by itself or in combination, with other

reagents for the depletion of infectious reagents, malignant cells, cancers, undesirable target cells or immunomodulation.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

5
Methods are provided for producing substantially human antisera in a heterologous host by immunizing the host with an immunogen. The host is characterized by; being at least substantially incapable of producing endogenous antisera and capable of predominantly producing substantially human polypeptide antisera upon exposure to an immunogenic
10 substance; and retaining its capability of rearranging the immunoglobulin locus and recombining the V, (D_H), J and C regions to produce substantially human protein antisera, which include at least one human immunoglobulin constant region and/or at least one human variable (V) region element. Of particular interest are constant regions of the subclasses of C_α or C_γ, including any of the C_γ subclasses 1, 2, 3 and 4. DNA fragments encoding human constant regions and variable elements are integrated into the genome by homologous recombination and replace the corresponding endogenous elements.

20 Various animals, particularly domestic animals, which can provide reasonable volumes of antisera may be employed. The animals generally are at least 1 kg, preferably 2 kg, and may be 5 kg or more when adult, although smaller animals can be used as appropriate. Also the gestation period should be less than 12 months, usually being in the range of 1 to 4 months. Illustrative animals include *Lagomorpha*, e.g. rabbit, ovine, bovine, canine, feline, equine, and the like, excluding murine. Of particular interest are animals where diversification of the antibody repertoire is accomplished predominantly by gene conversion
25 (i.e. rabbits, pigs, sheep, cattle). In these animals, replacement of the V region element proximal to the D region with a human V region element will result in the expression of the human V region element in the majority of immunoglobulins. The described genetic engineering approach of the subject invention is substantially easier than other approaches that have been performed with mice. In mice, however, diversification of the antibody
30 repertoire is accomplished predominantly by gene rearrangement.

Host cells, e.g. fibroblasts, keratinocytes, myocytes, hepatocytes, epithelial cells, or other cells which may be grown and expanded in culture and do not have a rearranged genome, are transformed (genetically modified) by the introduction of DNA fragments into the cells, where the fragments become integrated into the host genome. Introduction may be by a variety of methods, including bare DNA, transfection with a viral vector, fusion, biolistics, liposomes, etc. The particular method will be selected in accordance with the purpose of the introduction of the DNA and the efficiency of integration. Functional immunoglobulin light and heavy chain loci are modified by homologous recombination, by replacing at least a portion of the host heavy chain constant region with at least a functional portion of the human heavy chain constant region and if desired, analogously, the host light chain constant region with a human light chain constant region. Of particular interest is also the replacement of the V region most proximal to the D region with a human V region element. In this way, while some portions of the immunoglobulin are host sequences, the antisera is not likely to cause a strong immune response in view of the great variety of variable regions in the antisera. In animals, where antibody diversity is generated predominantly by gene conversion, replacement of the V region most proximal to the D region with a human V region element results in expression of the human V element in the majority of immunoglobulins. For the replacement of constant regions it is of particular interest to include at least about 2 of the 3 domains C_{H1} , C_{H2} , and C_{H3} of the constant region, particularly including C_{H3} . To the extent such antisera can function in a host, particularly an immunocompromised host, the reduced number of stages to attain hosts which produce such antisera is attractive.

For integration at a predetermined site, constructs are prepared which include, in sequence, the DNA fragment for integration and a first marker gene bordered by homologous sequences of at least about 30nt and a second marker gene, whereby homologous integration results in loss of the second marker gene. By having the second marker gene providing negative selection--cells with the second marker gene are selected against and removed from the cell mixture; by having the first marker gene providing positive selection--cells having the first marker gene are retained--by using a medium to which the second marker gene is sensitive. In this manner, those cells in which the construct is randomly integrated are decreased. By following with a medium selective for the first marker gene, cells not retaining

the first marker gene will be decreased. In this way, the remaining cells should be those having homologous recombination. Desirably, the cells are in a rapidly proliferating status, rather than a non-proliferating status. By employing a growth medium, such as RPMI1640 or DMEM, supplemented with FCS and growth factors, a growth cycle can be induced.

After the cells have been transformed or transfected, the cells are put in a selective medium in accordance with the marker employed, usually an antibiotic resistance or the tk gene. The cells are expanded in culture and then cloned. Individual cells in clones may then be screened for the desired genetic modification. Conveniently, PCR may be used to identify that the desired modification, deletion or integration, has taken place.

The genetic modifications may be a single modification or, if desired, after expansion of cells having the first modification, the cells may then be subjected to a second modification. For example, after replacing the heavy chain constant regions, one could replace the light chain constant regions.

Where an individual modification occurs, one can use a single marker for positive selection and use the same marker repetitively. Where two or more modifications to the same cell are generated, different positive selection markers should be used, in order to independently select at each stage. As already indicated, there are numerous antibiotic resistance genes, which genes may be used in combination, allowing for selection at each stage. Genes useful for selection include neo, tet, cam, tk, pen, mtX, etc. After the host cells have been modified and demonstrated to have the desired modification, the cells may then be fused with enucleated nuclear transfer unit cells, e.g. oocytes or embryonic stem cells, cells which are totipotent and capable of forming a functional neonate. Fusion is performed in accordance with conventional techniques which are well established. See, for example, Cibelli et al., Science (1998) 280:1256. Alternatively, enucleation of oocytes and nuclear transfer can be performed by microsurgery using injection pipettes. (See, for example, Wakayama et al., Nature (1998) 394:369) The resulting functional egg cells are then cultivated in an appropriate medium and transferred into synchronized recipients.

Another method for producing nuclear transfer unit cells is to introduce DNA constructs comprising human transgenes into fertilized eggs. The eggs may then be expanded to provide embryonic stem cells, which are screened for the desired genetic modification and subsequent embryo transfer into foster mothers, where the eggs are brought to term, and the resulting neonates screened for the modified genotype.

The resulting mutated hosts may then be used for breeding with other mutated hosts. For example, hosts having an altered heavy chain immunoglobulin locus may be bred with hosts having an altered light chain immunoglobulin locus to breed a host capable of producing substantially human polypeptide immunoglobulins. The hemizygous siblings containing the two mutated genes are then bred to produce homozygous siblings. Homozygosity may be readily determined by the absence of the undesired gene sequences. After each breeding, the host is assayed for the presence of the genetic modification in its cells, particularly the germ cells, and may be bred to a further generation, usually not more than three generations, to ensure that the modification is stably maintained through successive generations. The genomes of the various offspring may be analyzed for the maintenance of the genetic modifications or, as appropriate, the offspring may be analyzed for the biological change which the genetic modification generated.

Once the host has been generated, the host may now be used to produce antisera under a variety of conditions. Depending upon the use of the antisera, antigens, immunogens comprising a hapten covalently bonded to an antigen, organisms, e.g. viruses and unicellular organisms, alive, attenuated or dead, fragments of organisms, organelles, cells, particularly human cells or fragments of cells, or the like may be used. Thus the antisera may be directed to an antigen, a small organic molecule or a cell, where the various entities may be endogenous or exogenous to the human host. The immunization composition may be administered in any convenient manner, with or without an adjuvant, and may be administered in accordance with a predetermined schedule. The affinity for the immunization composition may then be monitored and the antisera collected when the antisera has the desired specificity and affinity. The affinity of the antisera generally will be at least about 10^{-7} , usually at least about 10^{-8} , preferably at least about 10^{-9} , or higher.

For some applications, one may use hosts in which the V element proximal to the D regions has been replaced with various human V region elements. In this way, different immune responses to the same immunogen will be obtained from the different hosts, where the variable region sequence may be as a result of gene conversion, providing different alleles. The antisera from the different hosts may be mixed to provide a broader repertoire of antibodies. Up to 10 or more different hosts may be employed, depending on the antigen of interest.

Antibody preparations are obtained by fractionating blood of genetically engineered animals expressing human sequence immunoglobulins. A concentrated immunoglobulin fraction may be prepared by chromatography (affinity, ionic exchange, gel filtration, etc.), selective precipitation with salts such as ammonium sulfate, organic solvents such as ethanol, or polymers such as polyethyleneglycol.

The fractionated antibodies may be dissolved or diluted in non-toxic, non-pyrogenic media suitable for intravenous administration in humans, for instance, sterile buffered saline. In some applications, antibody preparations may be applied directly onto epithelium. For such applications, fractionated antibodies may be dissolved in a water soluble gel such as KY-jelly and the like.

The antibody preparations used for administration are generally characterized by containing a polyclonal antibody population, having immunoglobulin concentrations from 0.1 to 100 mg/ml, more usually from 1 to 10 mg/ml. The antibody preparation may contain immunoglobulins of various isotypes. Alternatively, the antibody preparation may contain antibodies of only one isotype, or a number of selected isotypes.

In most instances the antibody preparation will consist of unmodified immunoglobulins. Alternatively, the immunoglobulin fraction may be subject to treatment such as enzymatic digestion (e.g. with pepsin, papain, plasmin, glycosidases, nucleases, etc.), heating, etc, and/or further fractionated.

5 The antibody preparations generally are administered into the vascular system, conveniently intravenously by injection or infusion via a catheter implanted into an appropriate vein. The antibody preparation is administered at an appropriate rate, generally ranging from about 10 minutes to about 24 hours, more commonly from about 30 minutes to about 6 hours, in accordance with the rate at which the liquid can be accepted by the patient. Administration of the effective dosage may occur in a single infusion or in a series of infusions. Repeated infusions may be administered once a day, once a week once a month, or once every three months, depending on the half-life of the antibody preparation and the clinical indication. For applications on epithelial surfaces the antibody preparations are applied to the surface in need of treatment in an amount sufficient to provide the intended end result, and can be repeated as needed.

10 The antibody preparations find use in their ability to bind and neutralize antigenic entities in human body tissues that cause disease or that elicit undesired or abnormal immune responses. An "antigenic entity" is herein defined to encompass any soluble or cell-surface bound molecules including proteins, as well as cells or infectious disease-causing organisms or agents that are capable at least capable of binding to an antibody and preferably also are capable of stimulating an immune response.

20 Administration of an antibody preparation against an infectious agent as monotherapy or in combination with chemotherapy results in elimination of infectious particles. A single administration of antibodies decreases the number of infectious particles generally 10 to 100 fold, more commonly more than 1000-fold. Similarly, antibody therapy in patients with malignant disease as monotherapy or in combination with chemotherapy reduces the number of malignant cells generally 10 to 100 fold, or more than 1000-fold. Therapy may be repeated over an extended amount of time to assure the complete elimination of infectious particles, malignant cells, etc. In some instances, therapy with antibody preparations will be continued for extended amounts of time in the absence of detectable amounts of infectious particles or undesirable cells. Similarly, the use of antibody therapy for the modulation of immune responses may consist of single or multiple administrations of therapeutic antibodies. Therapy may be continued for extended amounts of time in the absence of any disease symptoms.

The subject treatment may be employed in conjunction with chemotherapy at dosages sufficient to inhibit infectious disease or malignancies. In autoimmune disease patients or transplant recipients antibody therapy may be employed in conjunction with immunosuppressive therapy at dosages sufficient to inhibit immune reactions.

The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

Generation of transgenic rabbits expressing substantially human immunoglobulin

Exons encoding human constant region elements and variable region elements are integrated into the genome of rabbit fibroblasts by homologous recombination. Rabbit fibroblasts are transfected with various linearized DNA constructs containing human immunoglobulin locus elements. Successfully transfected cells are selected and used for the cloning of rabbits.

Cloning of rabbits

Mature Dutch Belton rabbits are superovulated by subcutaneous injection of follicle stimulating hormone (FSH) every 12 hours (0.3 mg x 2 and 0.4 mg x 4). Ovulation is induced by intravenous administration of 0.5 mg luteinizing hormone (LH) 12 hours after the last FSH injection. Oocytes are recovered by ovidual flush 17 hours after LH injection. Oocytes are mechanically enucleated 16-19 hours after maturation. Chromosome removal is assessed with bisBENZIMIDE (HOECHST 33342, Sigma, St. Louis, MO) dye under ultraviolet light. Enucleated oocytes are fused with actively dividing fibroblasts by using one electrical pulse of 180 V/cm for 15 us (Electrocell Manipulator 200, Genetronics, San Diego, CA). After 3-5 hours oocytes are chemically activated with calcium ionophore (6 uM) for 4 min (# 407952, Calbiochem, San Diego, CA) and 2 mM 6-dimethylaminopurine (DMAP, Sigma) in CR2 medium (Specialty Media, Lavalent, NJ) with 3 mg/ml bovine serum albumin (fatty acid free, Sigma) for 3 hours. Following the activation, the embryos are washed in hamster embryo culture medium (HECM)-Hepes five times and subsequently, cultivated in

CR2 medium containing 3 mg/mgl fatty-acid free BSA for 7 days at 37.8° C and 5%CO2 in air. Embryos are then transferred into synchronized recipients. Offsprings are analyzed by PCR for a segment of the transgene.

5 Binding of human antibodies expressed in rabbits to Hepatitis B surface antigen

Genetically engineered rabbits (as described above) are immunized intramuscularly with purified Hepatitis B surface antigen (HBsAg) (10µg in incomplete Freund's adjuvant) on day 0 and day 14. On day 28 animals are bled from the ear and serum is prepared. ELISA plates (NUNC, Denmark) are coated with 1 µg/ml HBsAg in PBS for 1 hour at room
10 temperature. Subsequently, available binding sites are blocked by incubation with 1% non-fat dry milk (NFM) in PBS (300 µl/well). Rabbit serum is diluted in PBS/1%NFM and added to the coated wells. After an incubation of 1 hour, the plates are washed 3 times with
15 PBS/0.05% Tween 20 and bound Ig is detected using goat anti-human Ig conjugated with horse-radish peroxidase. Conjugated goat antibody is detected using o-phenylenediamine dihydrochloride (Sigma) at 1 mg/ml. The colorimetric reaction is stopped by addition of 1 M HCl solution and the absorbance is measured at 490 nm. As a control serum from
20 non-immunized rabbits is used. Serum from non-immunized rabbits does not react with HBsAg. At a dilution of 1:100 the optical density measured in uncoated and HBsAg coated wells is below 0.4. In contrast, serum from immunized rabbits contains substantially human antibodies reactive with HBsAg. At a serum dilution of 1:100 the measured optical density is 2.8. Upon further dilution of the serum the measured optical density declines to 0.2 (at a dilution of 25600). No antibodies reactive with a goat anti-rabbit IgG-HRP conjugate can be detected. This demonstrates that the genetically engineered rabbits produce substantially human anti-HBsAg antibodies following immunization.

25 Complement mediated cytotoxicity of virus infection cell line using human antibodies

A human liver carcinoma cell line expressing HBsAg is labeled with 0.1 mCi ⁵¹Cr in 100 ul PBS for 1 hr at 37°C. Two thousand ⁵¹Cr-labeled cells are incubated with serum from genetically engineered rabbits expressing anti-HBsAg immunoglobulin (see above). After
30 two hours at 37°C the release of ⁵¹Cr into the supernatant is determined by measuring radioactivity using a scintillation counter. For the determination of maximum release, 1% Triton X100 is added. The degree of cell lysis is calculated as follows: %Lysis = CPM

experimental \pm CPM#spontaneous / CPM# total \pm CPM spontaneous. Incubation of labeled cells with serum (diluted 1:30) from non-immunized rabbits does not result in cell lysis (<10%). However, incubation of cells with serum from immunized rabbits causes 80% cell lysis. Inactivation of complement in the serum by heat treatment (56°C for 30 minutes) renders the serum from immunized rabbits inactive. These results demonstrate that substantially human antibodies produced by genetically engineered rabbits bind to HBsAg-positive cells and cause complement dependent lysis.

Treatment of animal with infection.

Substantially human immunoglobulin is purified from the serum of genetically engineered rabbits by ammonium sulfate precipitation and ion exchange chromatography. SCID-mice are injected with one million human liver carcinoma cells expressing HBsAg. Subsequently, 25 μ g immunoglobulin is injected peritoneally once per day. Animals treated with antibodies isolated from non-immunized rabbit serum die after about 60 days. This is similar to untreated recipients of liver carcinoma cells. In contrast, mice treated with antibodies isolated from immunized rabbit serum survive for more than 150 days. This demonstrates that human antibodies produced in genetically engineered rabbits are capable of eliminating human carcinoma cells from SCID-mice.

It is evident from the above results that by using genetically engineered rabbits expressing substantially human immunoglobulin genes, polyclonal antibody preparations against antigens, infectious particles, cancer cells, and the like can be generated. Such polyclonal antibody preparations can be used to treat patients suffering from an infectious disease or a malignancy. The antisera also can be used to modulate an immune response by elimination of cell sub-populations, cytokines, or the like. The human antibody preparation has a substantially reduced likelihood of engendering an immune response in human patients, as compared to heterologous antisera, it will have few side effects and it can be used safely with positive results.

All of the references cited herein are incorporated herein by reference as if each reference was individually wholly incorporated.

It will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

004020 " 653460

WHAT IS CLAIMED IS:

1. A polyclonal antisera composition of a nonhuman animal that specifically recognizes an immunogen, wherein said antisera composition is comprised predominantly of substantially human immunoglobulin protein molecules comprised of at least a portion of a human heavy chain polypeptide, wherein said substantially human immunoglobulin protein molecules specifically bind to said immunogen.
2. The polyclonal antisera according to Claim 1, wherein said transgenic nonhuman animal is immunized with said antigenic entity, weighs at least 1 kg and comprises at least a portion of functional human heavy chain immunoglobulin genes integrated by homologous recombination into its genome.
3. The polyclonal antisera composition according to Claim 1, wherein said transgenic nonhuman animal generates antibody diversity predominately by gene conversion.
4. The polyclonal antisera composition according to Claim 1, wherein said transgenic nonhuman animal is from the order *Lagomorpha*.
5. The polyclonal antisera composition according to Claim 1, wherein said portion of functional human heavy chain immunoglobulin genes comprises at least one constant region element.
6. The polyclonal antisera composition according to Claim 5, wherein said portion of functional human heavy chain immunoglobulin genes further comprises at least one variable region element.
7. The polyclonal antisera composition according to Claim 6, wherein said variable region element is the variable region element proximal to the D region.
8. The polyclonal antisera composition according to Claim 1, wherein said immunogen

004020 " 0555450

comprises a disease causing organism or antigenic portion thereof.

9. The polyclonal antisera composition according to Claim 1, wherein said immunogen is an antigen endogenous to humans.
10. The polyclonal antisera composition according to Claim 1, wherein said immunogen is an antigen exogenous to humans.
11. A transgenic nonhuman animal weighing at least 1 kg and comprising at least a portion of functional human heavy chain immunoglobulin genes integrated by homologous recombination into its genome, wherein said portion of functional human heavy chain immunoglobulin genes rearranges in frame with heavy chain immunoglobulin sequences endogenous to said nonhuman animal to encode functional, substantially human antibody molecules that comprise at least in part human heavy chain immunoglobulin polypeptide sequences, and wherein said animal predominantly produces said functional, substantially human antibody molecules when immunized.
12. A transgenic nonhuman animal weighing at least 1 kg and comprising at least a portion of functional human light chain immunoglobulin genes integrated by homologous recombination into its genome, wherein said human light chain immunoglobulin genes rearrange in frame with sequences endogenous to said nonhuman animal to encode functional, substantially human antibody molecules that comprise at least in part human light chain immunoglobulin polypeptide sequences.
13. The transgenic nonhuman animal according to Claim 11, wherein said transgenic nonhuman animal generates antibody diversity predominately by gene conversion.
14. The transgenic nonhuman animal according to Claim 11, wherein said transgenic nonhuman animal is from the order *Lagomorpha*.
15. The transgenic nonhuman animal according to Claim 11, wherein said portion of functional human heavy chain immunoglobulin genes comprises at least one constant

004020-4585450

region element.

16. The transgenic nonhuman animal according to Claim 15, wherein said portion of functional human heavy chain immunoglobulin genes further comprises at least one variable region element.
17. The transgenic nonhuman animal according to Claim 16, wherein said variable region element is the variable region element proximal to the D region.
18. The transgenic nonhuman animal according to Claim 12, wherein said human immunoglobulin light chain gene encodes the κ chain.
19. An antisera composition produced by the transgenic nonhuman animal according to Claim 11.
20. A method for neutralizing an antigenic entity in a human body component, said method comprising:
contacting said body component with an antisera composition according to Claim 1, whereby said substantially human immunoglobulin protein molecules in said antisera composition specifically bind and neutralize said antigenic entity.
21. The method according to Claim 20, wherein said antigenic entity is from an organism that causes an infectious disease.
22. The method according to Claim 20, wherein said antigenic entity is a cell surface molecule.
23. The method according to Claim 22, wherein said cell surface molecule is from a lymphocyte or an adipocyte.
24. The method according to Claim 20, wherein said antigenic entity is a human cytokine or a human chemokine.

004020" E5B5450

25. The method according to Claim 20, wherein said antigenic entity is a cell surface molecule on a malignant cancer cell.
26. A method of producing a transgenic nonhuman animal weighing at least 1 kg and comprising human immunoglobulin genes integrated by homologous recombination into its genome, wherein said animal predominantly produces functional, substantially human antibody molecules comprised at least in part of human immunoglobulin polypeptide sequences when immunized, said method comprising:
- producing a first mutated animal comprising heavy chain immunoglobulin loci where constant and/or variable region elements are replaced with at least a functional portion of the human heavy chain immunoglobulin locus by genetic alteration of a cell nucleus of said animal, introducing said cell nucleus into an enucleated nuclear transfer unit cell to provide a first embryonic stem cell, introducing said first nuclear transfer unit cell into a female recipient host to produce a first mutated neonate;
 - producing a second mutated animal comprising light chain immunoglobulin loci where constant and/or variable region elements are replaced with at least a functional portion of the human light chain immunoglobulin locus by genetic alteration of a cell nucleus of said animal, introducing said cell nucleus into an enucleated nuclear transfer unit cell to provide a second embryonic cell stem cell, introducing said second nuclear transfer unit cell into a female recipient host to produce a second mutated neonate; and
 - breeding mature first and second mutated neonates and selecting animals capable of producing substantially human antisera and being at least substantially incapable of producing endogenous antisera.
27. A method of producing a transgenic nonhuman animal weighing at least 1 kg and comprising human immunoglobulin genes integrated by homologous recombination into its genome, wherein said animal predominantly produces functional, substantially human antibody molecules comprised at least in part of human immunoglobulin polypeptide sequences when immunized, said method comprising:
- producing a mutated animal comprising heavy and light chain immunoglobulin loci where constant and/or variable region elements are replaced with at least a

004020 7E5B460

functional portion or the human heavy and/or light chain immunoglobulin locus by genetic alteration of a cell nucleus of said animal, introducing said cell nucleus into an enucleated nuclear transfer unit cell to provide a embryonic cell stem cell, introducing said nuclear transfer unit cell into a female recipient host to produce mutated neonate; and

breeding mature mutated neonates and selecting animals capable of producing substantially human antisera and at least substantially incapable of producing endogenous antisera.

28. The method according to Claim 26, wherein said nuclear transfer unit cell is an oocyte.
29. The method according to Claim 26, wherein said animal is from the order of *Lagomorpha*.
30. A method according to Claim 26, wherein said heavy chain locus comprises at least one constant region element.
31. A method according to Claim 26, wherein said heavy chain locus comprises at least one variable region element.
32. A method according to Claim 26, wherein said heavy chain locus comprises the variable region element proximal to the D region.

004020 " 2E6B460

HUMAN POLYCLONAL ANTIBODIES FROM GENETICALLY
ENGINEERED ANIMALS

ABSTRACT OF THE DISCLOSURE

Substantially human antisera are provided by genetically modifying a domestic animal generally weighing at least about 1 kg. The domestic animal is genetically modified by generating inactive heavy and light chain immunoglobulin loci and integrating at least functional portions of the human heavy and light chain immunoglobulin loci, whereby the human loci generate an immune response. The antisera find use in the treatment of diseases, immunocompromised patients and in case of transplantation.

004020" 2E5E6460

**COMBINED INVENTOR
DECLARATION AND POWER OF ATTORNEY**

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Human Polyclonal Antibodies From Genetically Engineered Animals

the specification of which

(check one) ☐ Is attached hereto.
☐ Was filed on _____ and has been assigned Serial Number _____.
☒ Was filed on February 4, 2000 as Attorney Docket No. ROBU.003.01US.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information known to me to be material to patentability of this application as defined in Title 37, Code of Federal Regulations, §1.56 and, if applicable, all such information under 37 CFR § 1.56 which became available between the national or PCT International filing date of the prior application and the filing date of this application.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			<u>Priority Claimed</u>	
(number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

Prior Foreign Application(s)			<u>Priority Claimed</u>	
(number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

Prior Foreign Application(s)

Priority Claimed

(number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
----------	-----------	------------------------	------------------------------	-----------------------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 USC §112 I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56, which became available between the filing date of the prior application and the national or PCT international filing date of this application:

60/118,810 (Application Serial No.)	2/5/99 (Filing Date)	Pending (Status)
----------------------------------------	-------------------------	---------------------

60/131,398 (Application Serial No.)	4/28/99 (Filing Date)	Pending (Status)
----------------------------------------	--------------------------	---------------------

60/134,674 (Application Serial No.)	5/18/99 (Filing Date)	Pending (Status)
----------------------------------------	--------------------------	---------------------

* (Application Serial No.)	(Filing Date)	(Status)
* designating the U.S.		

I hereby appoint:

BARBARA RAE-VENTER, Ph.D., Reg. No. 32,750
 BERTRAM I. ROWLAND, Ph.D., Reg. No. 20,015
 JENNIFER WAHLSTEN, Ph.D., Reg. No. P-46,226

as my attorneys or agents with full power of substitution and revocation to prosecute my above-identified application for Letters Patent and to transact all business in the Patent Office connected therewith.

Direct all telephone calls to Barbara Rae-Venter, Ph.D. at (650) 328-4400.

Address all correspondence to:

Barbara Rae-Venter, Ph.D.
 Rae-Venter Law Group, P.C.
 P. O. Box 60039
 Palo Alto, California 94306-0039

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued

thereon.

Full name of sole or first inventor: Jens-Ulrich Buelow

Inventor's signature: _____

Date: _____

Residence: Karlsruhe, Germany

Citizenship: Germany

Post Office Address: Flughafenstrasse 19, 76140 Karlsruhe, Germany

Full name of second joint inventor, if any:

Inventor's signature: _____

Date: _____

Residence: _____

Citizenship: _____

Post Office Address: _____

Full name of third joint inventor, if any:

Inventor's signature: _____

Date: _____

Residence: _____

Citizenship: _____

Post Office Address: _____

Full name of fourth joint inventor, if any:

Inventor's signature: _____

Date: _____

Residence: _____

Citizenship: _____

Post Office Address: _____